ImmuPharma, a specialized drug discovery and development pharmaceutical company, announced its Phase 3 clinical trial of Lupuzor (rigerimod), the company’s lead potential breakthrough lupus treatment candidate, has made progress and has begun dosing its first European patients. In its update, ImmunoPharma said the Lupuzor Phase 3 study will enroll…
Researchers at Sun Yat-sen University in China have found that a group of anti-nuclear antibodies that target double stranded DNA, anti-dsDNA, may cause inflammation in systemic lupus erythomatosus (SLE) patients, through the activation of a particular molecular inflammasome. The findings were revealed in the study “Anti-dsDNA antibodies bind to TLR4…
Four key Lupus advocacy groups will host a Lupus Patient-Focused Drug Development Meeting next spring called “Lupus: Patient Voices,” according to a news release. The groups, the Alliance for Lupus Research (ALR), the Lupus Research Institute (LRI), the Lupus and Allied Diseases Association (LADA), and the Lupus Foundation of America (LFA), will lead the…
A patient-centered lupus drug development meeting, “Lupus: Patient Voices”, will be held in spring 2017. The Alliance for Lupus Research (ALR), the Lupus and Allied Diseases Association (LADA), Lupus Foundation of America (LFA), and the Lupus Research Institute (LRI) will organize the event that will focus on patient viewpoints, daily impacts…
Resolve Therapeutics, a biopharma developing innovative therapies for Systemic Lupus Erythematosus (SLE) and Sjogrens syndrome, will present new data from two clinical studies at the EULAR Annual European Congress of Rheumatology, June 8-11, in London. The company’s scientific founder Dr. Keith Elkon will deliver the oral presentation “Immune Complex Bound…
Sanford Burnham Prebys Medical Discovery Research Institute researchers have uncovered a new protein called P-selectin glycoprotein ligand-1 (PSGL-1) that is involved in the regulation of T-cell immune responses, with implications in autoimmune diseases. The findings have recently been published in Immunity in a study titled “…
The Alliance for Lupus Research (ALR) partnered with Willie Colon, the former New York Jets offensive guard, for the second Annual Willie Colon Charity Golf Outing fundraiser benefitting the ALR Jean Davis Research Grant. Money raised at the event is used to further ALR-targeted research efforts. Other former National Football League players who attended…
Bridget Hood, a Lupus L.A. board member who lives with the disease, has published an editorial in a California newspaper to mark May —  Lupus Awareness Month — and to raise awareness of lupus and advocate for new research into potential treatments or a cure. Specifically, Hood called on policymakers to do…
Researchers have identified an enzyme called SHP-2 whose levels are significantly increased in blood samples of lupus patients and in systemic lupus erythematosus (SLE) mouse models, which can become a potential therapeutic target for patients suffering from this disease. The study, “Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus…
The U.S. National Institute of Allergy and Infectious Disease (NIAID) has awarded $225,000 to Karyopharm Therapeutics to advance the development of its SINE nuclear transport compound, KPT-350, to treat neurological, inflammatory and autoimmune diseases. The grant will be used in preclinical trials of the compound as a treatment for  systemic lupus erythematosus (SLE), which will…